Komipharm Applies for Accelerated Program of COVID-19 Treatment 'Panapix' to US FDA
[Asia Economy Reporter Minji Lee] Comipharm announced on the 8th that it has applied to the U.S. Food and Drug Administration (FDA) for the Coronavirus Treatment Acceleration Program (CTAP) to evaluate the safety and efficacy of PAX-1 (Panapix) in pneumonia patients caused by COVID-19.
The company stated, "This is to assess the effect of PAX-1 in preventing acute respiratory distress syndrome (ARDS) in infectious pneumonia patients caused by COVID-19," and added, "We plan to orally administer the treatment to 500 infectious pneumonia patients caused by COVID-19 over a total of 28 days."
Hot Picks Today
No Bacteria Detected in Arisu After 24 Hours of Repeated Drinking from a Tumbler
- Government Weighs 'Emergency Mediation'... Will It Be the Card to Stop Samsung Electronics Strike? [Why&Next]
- Despite Surprising $23 Billion Earnings, Cisco to Lay Off 4,000 Employees for Expanded AI Investment
- High-Net-Worth Investors Increase Stock Holdings: "Samsung and SK hynix Are Basic, Now Searching for the Next Opportunity" [Investment Strategies of the Wealthy] ⑧
- Police Officer Cycling on Day Off Rescues Woman Attempting to Jump from Hangju Bridge
Furthermore, the company explained, "If selected for CTAP, the drug development and testing process, which usually takes about 10 years, can be shortened to a few months," and added, "This will proceed according to the PAX-1 treatment development plan under the support program of the U.S. government."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
